Esperion Therapeutics (ESPR) Misses Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Esperion Therapeutics (ESPR) PT Raised to $130 at Needham & Company
May 8, 2015 7:46 AM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and boosted his price target on Esperion Therapeutics (NASDAQ: ESPR) to $130.00 (from $104.00), citing multiple value-creating events through year-end.
Esperion has submitted briefing documents to the FDA and expects to be able to hold... More
